OS Therapies Inc (OSTX) Stock Profile — Insider Trades & Financials

Net Income-$13.5M

EPS$-0.57

Market Cap$49.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Paul Romness

CEO & Executive Director

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Founded: 2018
Employees: 5
Headquarters: Grasonville, Maryland, United States

⚡

Core Efficiency

ROE?

220.83%

ROA?

-196.81%

D/E Ratio?

-1.95

📊

Profitability Ratios

Current Ratio?

0.03

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 25, 2026 (in 138 days)

Annual Report (10-K) — Based on filing pattern

Aug 25, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20255d after period end

Nov 14, 2025

10-QQ3 20250d after period end

Aug 18, 2025

10-QQ2 20255d after period end

May 15, 2025

10-QQ1 20252d after period end

Mar 31, 2025

10-KQ4 20243d after period end

Nov 15, 2024

10-QQ3 20244d after period end

Aug 14, 2024

10-QQ2 20240d after period end

May 20, 2024

10-QQ1 202411d after period end

Loading company sections...

OS Therapies Inc

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness